The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly and Company LLY reported third-quarter 2025 adjusted earnings per share (“EPS”) of $7.02, which beat the Zacks ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, ...

With quarterly revenue up 54% from a year ago, Eli Lilly raised it guidance for the year, with the company now expecting revenue in the range of $63 billion to $63.5 billion ...

A rendering of Eli Lilly's planned plant expansion in Pleasant Prairie. The company is preparing for a next phase on a site ...

Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares ...

Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.

"Every day, I got on the scales and I still weighed exactly the same as before," Leith, 85, told U.K. paper 'The Times' ...